Form 4: Royalty Pharma Director Gregory Norden Receives Stock Award

Director Gregory Norden of Royalty Pharma plc reports acquisition of 7,614 Class A Ordinary Shares through a restricted stock unit award.

Summary

• On May 13, 2025, Gregory Norden, a director of Royalty Pharma plc, acquired 7,614 Class A Ordinary Shares.
• The acquisition was through an award of restricted stock units under the company's 2020 Independent Director Equity Incentive Plan.
• These restricted stock units are scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date.
• Following the transaction, Norden directly owns 83,688 Class A Ordinary Shares.

Sentiment

Score: 7

Explanation: The document indicates a standard director compensation practice, which is generally viewed neutrally to positively as it aligns director interests with shareholders.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The vesting of the restricted stock units is contingent upon the terms of the 2020 Independent Director Equity Incentive Plan and the applicable award agreement.

Industry Context

Stock awards to directors are a common practice in publicly traded companies to incentivize and align their interests with those of shareholders. The specific terms of the award, such as vesting schedules, are tailored to the company's compensation policies and strategic goals.

Stakeholder Impact

• Shareholders may view the stock award positively as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

Royalty Pharma, Director, Gregory Norden, Stock Award, Restricted Stock Units, RPRX, Beneficial Ownership, Form 4